Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Gbathaton Feb 04, 2022 8:11am
78 Views
Post# 34396565

RE:RE:RE:enough suits!

RE:RE:RE:enough suits!BBall, I agree that these are interesting additions to the SAB, especially given their hospital affiliations.

The quote attributed to Dr. Cashman mentioned "broad" exerptise in neuro, but I suspect they were brought on for very specific reasons- advisement on clinical trial coordination from someone who manages a neuro-focused hospital, and advisement on collection and review of associated brain imaging and biomarker data.

I don't care if people here try to beat down the stock... I'm adding as opportunities arise. Our company has access to capital in the near term, so the SP is not terribly relevant at the moment, unless buying or selling.  But I am more in the holding category for the next year, again adding when opportunities arise.  Are these bashers annoying?  Yes, yes they are.  Though some are likely just expressing frustrations that we all share to some extent, as it is difficult to be patient when the opportunity before us (an that communicated for many years by management) is so great.

I have a high degree of confidence that this investment will make good money for me and help the world.  If all goes well, it could turn into a fortune for my kids and help me interact bettter with my grandkids when my brain starts failing someday.  

Best of luck to you, and thanks for being a voice in the wilderness.
<< Previous
Bullboard Posts
Next >>